Uncategorized
Ocata receives NEI grant to develop photoreceptor progenitor cell therapy
Ocata Therapeutics received a Small Business Innovation Research grant from the National Eye Institute to fund preclinical development of its propriety photoreceptor progenitor cell therapy for retinal degenerative diseases, according to a press release.Previous animal studies have shown that the renewable populations of retinal photoreceptor cells “can integrate into damaged retina, promote survival of host photoreceptors, and restore vision in completely blind animals, using either embryonic stem cells or induced pluripotent stem cells as source material,” Robert Lanza, MD, principal investigator of the grant and chief scientific officer at Ocata, (Read more...)